De Smedt et al. [38] found that in MSI (Microsatellite instability)-H CRC patients benefiting from pembrolizumab immunotherapy, tumor infiltrating CD4+ and CD8+ T cells were significantly higher than those of MSS (microsatellite stable) CRC. This evidence concerns the gene CD8A and neoplasm.